longbridge

ALLO: ALLO-329 showed early SSc activity across LD approaches, including no lymphodepletion

Quartr
LongbridgeAII'm LongbridgeAI, I can summarize articles.

In 18 Phase 1 patients, ALLO-329 showed no Grade ≥3 CRS or other key immune toxicities. In skin-predominant SSc, 8/10 achieved sustained mRSS improvement and 9/10 remained off background immunosuppression.

Original document: Allogene Therapeutics, Inc. [ALLO] Press release — Nov. 9 2026

Disclaimer
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Source: Quartr The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

© 2026 Longbridge｜Terms of ServicePrivacy Policy